- News & Analysis
- Home
- Latest News
- Reports
- Podcasts
- The CVC Funding Round Database
- The CVC Directory
- University
- Video
- Subscribe
- Newsletters
- Job Postings
- Events
Page 116
Weizmann Institute duo nab $12m
The funding will be funnelled into an unnamed p53 suppressor-focused oncology Weizmann spinout and ultrasound guidance device maker On-Sight Medical.
Mar 22, 2019Sapien Cyber locks down funding
Oil and gas exploration company Woodside Energy was sufficiently intrigued in its earlier development pact with ECU-founded Sapien Cyber to purchase a 10% stake.
Mar 20, 2019Qart Medical instills funding
TAU-founded Qart Medical has been backed by the university’s Technology Innovation Momentum Fund and Chartered Investment Managers, itself a partner in TAU Ventures.
Mar 19, 2019Corporate venturing deal net: 11-15 March 2019
Each Friday the Global Corporate Venturing Deal Net rounds up the week’s smaller deals and tracks the emerging companies accessing corporate funds.
Mar 15, 2019Gencove adds $3m to funding sequence
New York Genome Center-founded Gencove has added $3m from investors including Alexandria Venture Investments to bring its genomics testing kit to new markets.
Mar 15, 2019Phasecraft executes funding
Based on UCL and Bristol research, Phasecraft is a member of a UK government-backed quantum collaboration driven by both universities together with the Google Quantum AI Lab.
Mar 15, 2019Sharpen phones IU in $15m round
IU Philanthropic Venture Fund was among the investors in the contact centre platform creator's round, which will help grow the business through recruitment and product development.
Mar 15, 2019Well Doc recuperates with $1.6m
Scotiabank has supplied University of Calgary-affiliated Well Doc Alberta with funding under a pact signed when it bought MD Financial Management last year.
Mar 14, 2019Parkwalk shifts return in Animal Dynamics
Parkwalk Advisors has sold on most of its stake in Oxford-founded drone designer Animal Dynamics, securing a 6.9 times return.
Mar 14, 2019CIC turns up for Gyroscope
Gyroscope Therapeutics recently commenced phase 1/2 clinical trials on a retinal gene therapy for dry age-related macular degeneration.
Mar 11, 2019About us
GCV provides the global corporate venturing community and their ecosystem partners with the information, insights and access needed to drive impactful open innovation. Across our three services - News & Analysis, Community & Events, and the GCV Institute - we create a network-rich environment for global innovation and capital to meet and thrive. At the heart of our community sits our membership, providing privileged access to all our services and resources.
Navigation
test regLogin
Not yet subscribed?
We use cookies to enhance your browsing experience and analyse our traffic. By clicking "Accept All", you consent to our use of cookies. Accept Read MorePrivacy & Cookies PolicyPrivacy Overview
This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.


